Cell-culture flu vaccines shipped from Novartis plant for 2014-5 season

By Dan Stanton contact

- Last updated on GMT

Cell-culture flu vaccine shipped from Novartis plant for 2014-5 season

Related tags: Influenza vaccine, Influenza

Novartis has shipped the first of its cell-culture - rather than chicken egg - based vaccines for the 2014-2015 flu season from its North Carolina facility.

The plant in Holly Springs, North Carolina, received a license from the US Food and Drug Administration (FDA) in June to manufacture Flucelvax and this week celebrated the first shipments of the vaccine Flucelvax from the facility for the 2014-2015 flu season with a ceremony attended by among others, Governor of North Carolina, Pat McCrory.

Flucelvax is the only flu vaccine manufactured using cell-culture technology, rather than influenza strains being grown and harvested in chicken eggs and, according to the Swiss Biopharma, is “the first major innovation in influenza vaccine production in more than 40 years.”

Furthermore, “the manufacturing process does not need advance planning, as frozen cell-culture stocks are readily available, and can be rapidly expanded to initiate production of vaccines in the event of a pandemic.”

The cell-culture-based influenza vaccine production takes place in closed and sterile bioreactors that amplify the virus production in Madin-Darby Canine Kidney (MDCK) cell lines, derived from a female cocker spaniel in 1958​.

The process consists of vaccine seed strains being provided to Novartis by the World Health Organization (WHO) from reference centres, while the MDCK cell line is grown in suspension for flu vaccine production, facilitating scalability. The virus is then propagated, purified in an automated and closed system, formulated and filled.

Novartis’ manufacturing facility comprises 44,120m2​ of space and employs 550 members of staff. It has the capability to produce 200 million adjuvanted doses of pandemic influenza vaccine within six months of the declaration of an influenza pandemic.

Related topics: Upstream Processing, Facilities, Cell lines

Related news

Show more

Related products

show more

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...


Inline diafiltration enables continuous processing

Pall Life Sciences | 13-Feb-2018 | Application Note

The Cadence inline diafiltration (ILDF) device is designed for continuous processing, in-process buffer exchange or contaminant removal in various processes...

Discover Fast and Simple Water Intrusion Testing

Discover Fast and Simple Water Intrusion Testing

Pall Life Sciences | 13-Nov-2017 | Application Note

At Pall we have supported the water intrusion test for more than 20 years and we developed the Palltronic® AquaWIT IV system to deliver fast and simple...

Related suppliers